A Phase I Trial of Liposomal Doxorubicin, Bevacizumab and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies

PURPOSE: Liposomal doxorubicin (D) and bevacizumab (A) are active single agents in gynecologic and breast malignancies which share a resistance mechanism: up-regulation of hypoxia inducible factor (HIF-1α). We therefore added temsirolimus (T), which inhibits HIF-1α, to D and A (DAT). Trial objective...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Moroney, John W., Schlumbrecht, Matthew P., Helgason, Thorunn, Coleman, Robert L., Moulder, Stacy, Naing, Aung, Bodurka, Diane C., Janku, Filip, Hong, David S., Kurzrock, Razelle
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3207033/
https://ncbi.nlm.nih.gov/pubmed/21890452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-0666
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky